Ribosome and Myocardial Infarction

Myocardial Infarction (MI), more commonly known as a heart attack, is a serious health issue that takes place when the heart muscle doesn't receive enough blood due to obstructions. These obstructions typically result from the accumulation of substances such as fat and cholesterol, leading to plaque formation in the coronary arteries - the key blood suppliers to the heart muscle. Ribosomes, the complex structures that are key for protein production in all living organisms, are increasingly being explored for their role in MI. These dynamic entities are integral to a multitude of cellular functions ranging from cell growth and replication, to cellular communication, DNA repair, and gene expression. Their connection to MI is currently a focal point of scientific examination, as it could provide vital comprehension of the molecular underpinnings of heart disorders.

The Role of Ribosomes in Myocardial Infarction

Understanding MI fundamentally stems from the understanding that it's typically caused by an obstruction in the coronary artery. This, in turn, restricts the flow of blood to the heart muscle. Multiple studies propose a significant link between MI and defective ribosomes. Components such as nucleolin (Ncl), ribosomal RNA (rRNA), ribosomal protein L9 (RPL9), and ribosomal protein L26 (RPL26) have been observed to diminish in instances of MI-related ribosomal dysfunction. Interestingly, Ncl appears to enhance a desirable macrophage response, thereby bolstering heart function during MI. The key component of cellular clean-up process or autophagy, if deleted or inhibited, can lead to heart dysfunction and changes in heart structure after MI. Interestingly, the Ncl/autophagy signaling pathway appears to be active in damaged heart muscle tissue. Furthermore, ribosomal proteins RPL9 and RPL26 are now being considered as potential targets for MI diagnosis or treatment.

Fig. 1 Ribosome dysfunction and MI.¹

Potential Therapies for Myocardial Infarction Targeting Ribosomes

Several promising strategies for utilizing ribosomes in treatments include influencing ribosomal growth and protein creation. This may potentially lessen the damage caused by MI and improve overall heart performance. Scientists are actively examining the part played by ribosomes in MI to discover potential new treatment targets.

• The regulation of Nucleolin (Ncl): Ncl has been discovered to boost M2 macrophage polarization, which can improve the functioning of the heart during MI. Controlling Ncl's levels or activity could provide a possible treatment strategy for MI.
• The regulation of Autophagy: Studies have revealed that disabling or inhibiting genes related to autophagy can worsen heart function and heart remodeling after a MI. Consequently, managing autophagy pathways holds potential as a treatment for MI.
• The regulation of Ribosomal proteins: Ribosomal proteins, such as RPL9 and RPL26, are seen as potential markers for diagnosing or treating MI. Manipulating the expression or activity of these vital proteins could result in therapeutic rewards for MI patients.
• Inhibitors targeting Ribosome biography: Inhibiting ribosome biography carries potential as a treatment strategy for MI. Targeting the procedures implicated in ribosome structure and performance could interrupt protein creation and potentially weaken the pathological processes linked to MI.
• Ribosome-targeted antibiotics: Antibiotics aimed at bacterial ribosomes could have potential therapeutic use cases in MI. These specific antibiotics could potentially control the microbiome and lower inflammation, which frequently accompanies MI.

To sum it up, associating ribosome-related phenomena with the root cause of myocardial infarction offers an intriguing model for categorizing at-risk patients and rethinking our grasp of the disease. It pioneers the development of individualized treatments targeting the ribosomal mechanisms, unfolding potential opportunities for therapeutic interference that has yet to be fully utilized.

At Creative Biolabs, our adept team, with a broad knowledge base in ribosomal research, is always ready to offer comprehensive services. These include tailored Ribosome Separation and Extraction Services as well as Ribosome Analysis Services, catered to our worldwide clientele. Should there be any specific requirements or if further information is needed about these services, feel free to reach out to us. We are more than happy to provide comprehensive information and a quote for you.

Reference

1. Jiao, Lijuan, et al. "Ribosome biogenesis in disease: new players and therapeutic targets." Signal Transduction and Targeted Therapy 8.1 (2023): 15.